Background on the issue your vision is tackling: 

Unequal distribution of pandemic-related products (incl. vaccines, therapeutics and diagnostics)

• Absence of a functional global supply chain and logistics network (incl. in inter-pandemic times).
  • No agreement on type and size of products needed for robust pandemic PPP, costs, logistics for strategic stockpiles, no regular epidemiologic risk-assessment.
  • Limited regional and multilateral purchasing mechanisms, limited transparency in cost and pricing of elements along supply chain (e.g. raw materials and other inputs needed for sustainable production of pandemic-related products such as active pharmaceutical ingredients).
• Unequal global distribution of manufacturing capacity of pandemic-related products, notably with regard to LMICs.
• Unequal distribution of research and development capacities of pandemic-related products, limited knowledge-sharing mechanisms and limited transparency on R&D spending

--

Notes from backcasting exercise:

Collective brainstorming on the following questions:

• Which policy measures should be taken?
• Who should act in CH, internationally? → 3 policy angles (multilateral level, CH policies at the national level + through engagement abroad e.g. development policy)

• Vision: 2040 "Taking Down the Fance in Equity"
  • Pathogen and Data sharing as a Global Public Good
  • Global Pooling for R&D
  • Capacity Building
• 2030
  • Establishment of a universal purchasing platform
  • Establishment of a legal framework ensuring purchasing by pooled body
  • Equitable development support and funding within LMIC for capacity building (infrastructure & education)
• 2026
  • Consistent reporting of disease cases of potential international concern (incentivization -> TBD)
  • Decentralization of the production supply chain of medical goods (diagnostics, vaccines, therapeutics)
• 2024
  • Continuous R&D (tech, AI, medical products)
  • Greater investment into surveillance, M&E
  • Funded through DAH & earmarked contributions